SCHEMBL20102811

SCHEMBL20102811

C=C(C)NCCCCCCCC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
EPHX1 P07099 4/20 0.37
LMNA P02545 2/20 0.37
PAOX Q6QHF9 2/20 0.33
KDM4C Q9H3R0 2/20 0.33
KDM4A O75164 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
ADRA1A P35348 1/20 0.32
SIRT6 Q8N6T7 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
GNAI3 P08754 1/20 0.32
GNAO1 P09471 1/20 0.32
GNAI1 P63096 1/20 0.32
MMP8 P22894 1/20 0.32
ALDH1A1 P00352 2/20 0.31
ALDH1A2 O94788 1/20 0.31
ALDH2 P05091 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23451084 1.00 KDM4E (0.39) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL20714652 1.00 KDM4E (0.39) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL15583521 0.98 LMNA (0.39) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL14269798 0.91 LMNA (0.35) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL25517190 0.86 LMNA (0.43) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL24103200 0.83 KDM4E (0.52) KDM4EMAPK1HIF1AEPHX1PAOX
SCHEMBL19058821 0.81
SCHEMBL21107585 0.81 LMNA (0.36) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL23807229 0.81 LMNA (0.36) KDM4EMAPK1HIF1AEPHX1LMNA
SCHEMBL21105933 0.81 LMNA (0.36) KDM4EMAPK1HIF1AEPHX1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10280447-B2 Substituted imidazo[1,2-A]pyrazines tethered to energy acceptors PROMEGA CORPORATION (US) 2019-05-07 US disclosed
US-20180119200-A1 COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280447-B2 Substituted imidazo[1,2-A]pyrazines tethered to energy acceptors GLB1, AADAC, MRPL21 KDM4E 3737/4885MAPK1 3436/4885HIF1A 2537/4885
US-20180119200-A1 COELENTERAZINE ANALOGUES TETHERED TO ENERGY ACCEPTORS GLB1, SI, AADAC KDM4E 3595/4885MAPK1 4858/4885HIF1A 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.